Pharmacokinetics and safety of subcutaneous nivolumab: results from the phase I/II CheckMate 8KX study
Background CheckMate 8KX was a phase I/II study investigating the pharmacokinetics and safety of subcutaneous (SC) nivolumab±recombinant human hyaluronidase PH20 (rHuPH20).Methods Patients with advanced solid tumors who were immune-checkpoint inhibitor-naïve were included. In parts A and B, patients...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
BMJ Publishing Group
2025-10-01
|
| Schriftenreihe: | Journal for ImmunoTherapy of Cancer |
| Online-Zugang: | https://jitc.bmj.com/content/13/10/e011918.full |
| Tags: |
Keine Tags, Fügen Sie das erste Tag hinzu!
|
